Drug Development Laboratories Molecular Biology 
BMG Labtech
MARCH 11, 2024
Enzyme-Linked Immunosorbent Assays (ELISAs) are an essential technique in today’s laboratory with many applications in the life sciences. They are often the method of choice to detect or measure specific biological molecules (analytes) for diagnostics, drug discovery or fundamental research.
Drug Target Review
FEBRUARY 19, 2024
I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. Biochemistry and molecular biology fascinated me in school. I am proud to have contributed to the advancements in monoclonal antibody discovery and development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
JULY 17, 2024
Together, the tools estimate how a drug may impact diverse outcomes of interest to drug developers: general cellular health, pharmacokinetics, and heart and liver function. Seal began this work after wondering if more toxicology insights could be gleaned from a drug candidate’s chemical structure. Seal S, et al.
The Pharma Data
FEBRUARY 25, 2022
. “The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. 25) in the journal Communications Biology.
Drug Target Review
OCTOBER 3, 2024
In 2024 alone, almost 50 antibody drug candidates are anticipated to enter regulatory review, the majority of which are mAbs. Aside from the advent of complex antibody-based drugs, the industry is facing some additional changes which are shaping drug development. Methods in Molecular Biology. 2021;291–306.
Conversations in Drug Development Trends
NOVEMBER 12, 2024
These advanced therapeutics harness the power of molecular biology to improve human health. Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys. Modifying and expanding the cells in a GMP laboratory.
Vial
MARCH 1, 2024
billion in 2023 attributable to its laboratory products and biopharma services segment (53.8% By type of service, clinical research services accounted for the lion’s share of the North American CRO services market, followed by early-phase development services, laboratory services, and consulting services. US), IQVIA Inc.
Expert insights. Personalized for you.
98 
Let's personalize your content